Ipca Laboratories Limited

Nellithanath Thankachen Byju

Ashok Kumar

Satish Rajanikant Soudagar

Gaurav Sahal

Arpana Prashant Mathur

Sanjay Pandurang Gawade

Dinesh Kanji Bhadra

Devki Moje

Dharmendra Singh

Suneel Yeshwant Dike

Pramil Kumar Mathur

Brajesh Sharma

Swapnil Shreekant Kore

Vitthal Suryabhan Buchude

New compounds, namely, (7aS,2'S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.

Anti-thrombotic compounds

The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.

Methods for the treatment or prophylaxis of thrombosis or embolism

Solid forms of methyl (7aS,2'S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate

Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as 'Form IPCA-ATO,' and the preparation thereof.

Process for preparation of atovaquone and novel intermediates thereof

Growing community of inventors

Mumbai, India

Nellithanath Thankachen Byju